Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

Kim Fox, Ian Ford, P Gabriel Steg, Michal Tendera, Roberto Ferrari, BEAUTIFUL Investigators, Michael Frenneaux

Research output: Contribution to journalArticlepeer-review

871 Citations (Scopus)

Abstract

Ivabradine specifically inhibits the I(f) current in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function. We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease and left-ventricular systolic dysfunction.
Original languageEnglish
Pages (from-to)807-16
Number of pages10
JournalLancet
Volume372
Issue number9641
DOIs
Publication statusPublished - 6 Sep 2008

Keywords

  • Aged
  • Benzazepines
  • Coronary Disease
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Heart Rate
  • Hospital Mortality
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Ventricular Dysfunction, Left

Cite this